Cargando…

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism

Direct oral anticoagulants (DOACs) apixaban and rivaroxaban are broadly used in the management of venous thromboembolism (VTE). Although not routinely required, measurement of their plasma concentration is advised for an increasing number of indications. Due to the lack of therapeutic ranges, curren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reda, Sara, Rudde, Eva, Müller, Jens, Hamedani, Nasim Shahidi, Oldenburg, Johannes, Pötzsch, Bernd, Rühl, Heiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143219/ https://www.ncbi.nlm.nih.gov/pubmed/35629372 http://dx.doi.org/10.3390/life12050705

Ejemplares similares

Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study
por: Reda, Sara, et al.
Publicado: (2022)

Assay for ADAMTS-13 Activity with Flow Cytometric Readout
por: Müller, Jens, et al.
Publicado: (2022)

Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels
por: Hamedani, Nasim Shahidi, et al.
Publicado: (2022)

Aptamer loaded superparamagnetic beads for selective capturing and gentle release of activated protein C
por: Hamedani, Nasim Shahidi, et al.
Publicado: (2022)

Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants
por: Reda, Sara, et al.
Publicado: (2020)

Impaired in vivo activated protein C response rates indicate a thrombophilic phenotype in inherited thrombophilia
por: Reda, Sara, et al.
Publicado: (2022)

Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics
por: Reda, Sara, et al.
Publicado: (2021)

PC Deficiency Testing: Thrombin-Thrombomodulin as PC Activator and Aptamer-Based Enzyme Capturing Increase Diagnostic Accuracy
por: Reda, Sara, et al.
Publicado: (2021)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion
por: Rühl, Heiko, et al.
Publicado: (2015)

Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII
por: Hamedani, Nasim Shahidi, et al.
Publicado: (2021)

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
por: Al Yami, Majed S., et al.
Publicado: (2023)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation
por: Rühl, Heiko, et al.
Publicado: (2022)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations
por: Leven, Cyril, et al.
Publicado: (2023)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study
por: Rühl, Heiko, et al.
Publicado: (2014)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2015)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma
por: Friedrich, Max Julian, et al.
Publicado: (2018)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Apixaban/heparin/rivaroxaban: Melaena and thrombocytopenia: 2 case reports
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7420egk1t9sijangcuvdaot684